Ivabradine for treatment of stable angina pectoris
被引:0
|
作者:
Ranil de Silva
论文数: 0引用数: 0
h-index: 0
机构:Royal Brompton and Harefield NHS Trust,Department of Cardiology
Ranil de Silva
Kim M. Fox
论文数: 0引用数: 0
h-index: 0
机构:Royal Brompton and Harefield NHS Trust,Department of Cardiology
Kim M. Fox
机构:
[1] Royal Brompton and Harefield NHS Trust,Department of Cardiology
[2] National Heart and Lung Institute,undefined
[3] Imperial College London,undefined
来源:
Nature Reviews Cardiology
|
2009年
/
6卷
关键词:
D O I:
暂无
中图分类号:
学科分类号:
摘要:
The ASSOCIATE study investigators have reported that the If current inhibitor, ivabradine, is safe, improves exercise performance, and delays the development of ischemia in patients with chronic stable angina being treated with atenolol. Ivabradine should be considered in the medical management of symptom-limited patients with angina, when heart rate is suboptimally controlled.